Understand the source comparison
KLOW Side Effects Long Term Research: Methodology Comparison
Acute Phase RCT (Switzerland, 2023) 12 weeks 42 healthy adults Cognitive performance, adverse event incidence Short duration. No data beyond 3 months Rodent Long-Term Model (Neuropeptides, 2025) 180 days (rat equivalent ~12–15 years human) 60 rats Organ histol
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Acute Phase RCT (Switzerland, 2023)
- 12 weeks
- 42 healthy adults
- Cognitive performance, adverse event incidence
- Short duration. No data beyond 3 months
- Rodent Long-Term Model (Neuropeptides, 2025)
- 180 days (rat equivalent ~12–15 years human)
- 60 rats
- Organ histology, liver/kidney biomarkers, behavioral testing
- Species translation gap. Rodent metabolism differs significantly
- Compassionate Use Observational Cohort (unpublished)
- 6–9 months
- 18 participants
- Patient-reported outcomes, thyroid panels, lipid markers
- No placebo control, small N, confounding variables
- User Forum Aggregation (Reddit/Longecity)
- Variable (2–18 months)
- ~200 self-reported cases
- Subjective symptom tracking
- No verification, selection bias, no baseline labs
- Mechanistic Analog Studies (Semax, Selank)
- 6–24 months
- 150+ across multiple trials
- Immunomodulation markers, endocrine function
- Different peptide sequences. Limited direct applicability to KLOW